SAN DIEGO, July 14, 2021 /PRNewswire/ -- Evofem
Biosciences, Inc., (NASDAQ: EVFM) today provided a preliminary look
at Phexxi® (lactic acid, citric acid and potassium
bitartrate) data for the second quarter of 2021 and revealed new
insights into the demographics of women who are using this
hormone-free contraceptive method.
- More than 14,000 Phexxi units were dispensed in the second
quarter of 2021.
- Over 5,400 healthcare providers prescribed Phexxi in the second
quarter of 2021.
- Over 7,000 healthcare providers have prescribed Phexxi since
- 60% of new Phexxi users are between the ages of 18 to 34
- For more than 50% of women converting to Phexxi, their last
prior contraceptive used was hormonal.
"The volume of women switching from hormonal birth control to
Phexxi indicates a movement is happening," said Saundra
Pelletier, Chief Executive Officer of Evofem Biosciences. "Women
are seeking a healthy lifestyle and choosing Phexxi for
hormone-free contraception is a natural fit."
The Company will discuss Phexxi trends and other key metrics in
detail on its second quarter earnings call in August. Call details
and access information will be announced in late July.
About Evofem Biosciences
Evofem Biosciences, Inc.,
(NASDAQ: EVFM) is developing and commercializing
innovative products to address unmet needs in women's sexual
and reproductive health, including hormone-free, woman-controlled
contraception and protection from certain sexually transmitted
infections (STIs). The Company launched its first FDA-approved
commercial product, Phexxi® (lactic acid,
citric acid and potassium bitartrate), in the United
States in September 2020. The Company is evaluating lead
product candidate EVO100 for the prevention of
trachomatis and Neisseria
gonorrhoeae infection in women in the ongoing Phase 3
clinical trial, 'EVOGUARD.' For more information, please
Phexxi® is a registered trademark of Evofem
Phexxi is an
on-demand method of birth control used to prevent pregnancy.
Phexxi is not
effective when used after sex. For more
information about Phexxi, talk to your healthcare provider and see
full Product Information, which is available
IMPORTANT SAFETY INFORMATION
- Rare cases (0.36%) of bladder and kidney infection have been
reported. If you have a history of urinary tract problems that keep
coming back, you should not use Phexxi.
- Contact your healthcare provider if you are experiencing
genitourinary side effects such as vaginal burning, itching,
discharge, genital discomfort (including in male partners), yeast
infection, urinary tract infection or bacterial vaginosis.
- Phexxi does not protect against any sexually transmitted
infections, including HIV.
Please report side effects by contacting Evofem
Biosciences toll-free at 1-833-EVFMBIO
or contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
This press release includes
"forward-looking statements," within the meaning of the safe harbor
for forward-looking statements provided by Section 21E of the
Securities Exchange Act of 1934, as amended, and the Private
Securities Litigation Reform Act of 1995. Various factors could
cause actual results to differ materially from those discussed or
implied in the forward-looking statements, and you are cautioned
not to place undue reliance on these forward-looking statements,
which are current only as of the date of this press release. Each
of these forward- looking statements involves risks and
uncertainties. Important factors that could cause actual results to
differ materially from those discussed or implied in the
forward-looking statements, or that could impair the value of
Evofem Biosciences' assets and business, are disclosed in the
Company's SEC filings, including its Annual Report on Form 10-K for
the year ended December 31, 2020 filed with the SEC
on March 4, 2021. All forward-looking statements are expressly
qualified in their entirety by such factors. The Company does not
undertake any duty to update any forward-looking statement except
as required by law.
Mobile: (718) 490-3248
View original content to download
SOURCE Evofem Biosciences, Inc.